莱斯康制药 LXRX 深 沪
等待开盘 09-17 09:30:00 美东时间
1.10
-0.020
-1.79%
华盛通- 最 高1.14
- 今 开1.14
- 成交量 145.73万股
- 最 低 1.09
- 昨 收 1.12
- 总市值 3.99亿
- 52周最高 2.175
- 市盈率 静 --
- 换手率 0.40%
- 52周最低 0.2836
- 委 比 87.60%
- 总股本 3.63亿
- 历史最高 22.96
- 量 比 0.79
- 振 幅 4.46%
- 历史最低 0.2836
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
Lexicon Pharmaceuticals is presenting clinical data on pilavapadin, an investigational AAK1 inhibitor for diabetic peripheral neuropathic pain (DPNP), at three medical meetings. The first presentation will be at NeuroDiab on September 13, 2025, followed by EASD on September 17, 2025, and Arrowhead’s Pain Summit on October 13, 2025. Rodica Pop-Busui, M.D., Ph.D., will present at the first two meetings, while Suma Gopinathan, Ph.D., will present th...
09-11 12:30
Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes
<p>Lexicon Pharmaceuticals submitted additional clinical data to the FDA from third-party funded studies to address concerns raised in the December 2024 complete response letter regarding Zynquista's potential risks. The data aims to support the resubmission of the New Drug Application for Zynquista as a treatment for adults with type 1 diabetes. FDA feedback is expected by the end of September. The company acknowledges strong patient support for...
09-08 12:30
Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025
<p>Lexicon Pharmaceuticals will present new data on pilavapadin, an AAK1 inhibitor, showing its effectiveness in reducing neuropathic pain in preclinical models of chemotherapy-induced peripheral neuropathy (CIPN) and multiple sclerosis (MS) at the 9th International Congress on Neuropathic Pain in Berlin. The findings suggest the potential of pilavapadin for treating additional neuropathic pain conditions beyond diabetic peripheral neuropathic pa...
09-04 12:30
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
Lexicon Pharmaceuticals will present data on the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP) at PAINWeek 2025. The study highlights patient experiences despite using available pain relievers and aims to inform the development of pilavapadin, a potential treatment for DPNP. Pilavapadin, a selective AAK1 inhibitor, received Fast Track designation from the FDA. Lexicon is focused on advancing innovative therapies...
09-03 12:30
美股大行评级 | 潜在涨幅91.64%！曼恩凯德生物医疗获HC Wainwright升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持曼恩凯德生物医疗"买入"评级，目标价从9美元升至11美元；杰富瑞：维持Ionis Pharmaceuticals"买入"评级，目标价从83美元升至96美元
09-03 10:20
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
Lexicon Pharmaceuticals announced that sotagliflozin, a dual sodium-glucose cotransporter inhibitor, consistently reduced heart failure endpoints and major adverse cardiovascular events (MACE) across all age groups, including older adults. A pooled analysis of data from the SCORED and SOLOIST-WHF studies, involving nearly 12,000 participants with type 2 diabetes and chronic kidney disease or worsening heart failure, showed a significant reduction...
09-02 12:30
Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences
Lexicon Pharmaceuticals, Inc. announced that its management will participate in fireside chats at Citi's Biopharma Back to School Conference on September 3 at 1:45 p.m. ET and at the H.C. Wainwright Global Investment Conference on September 8 at 3:00 p.m. ET. The live events and replays can be accessed via the Company’s website. Lexicon, a biopharmaceutical company, focuses on pioneering medicines through its Genome5000 program, targeting disease...
08-27 12:30
跨国药企洞察｜左手诉讼 右手创新 发起132诉讼的诺和诺德能否赢得“反击战”？
（来源：动脉新医药） 编者按： 全球视野下的跨国药企深度洞察——创新、博弈与中国答卷 在全球医药产业发展的宏大叙事中，跨国药企始终扮演着关键角色——他们...
08-15 17:54
美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $1.9
Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $1.2 to $1.9.
08-08 06:49
